Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
BLIS Technologies Limited ( (NZ:BLT) ) just unveiled an announcement.
BLIS Technologies reported a 16% rise in FY26 revenue to $14.7m, driven by strong growth in B2B ingredient and private label sales and continued B2C momentum in New Zealand. Underlying EBITDA reached $1.8m after adjusting for a one-off $0.9m supply chain cost, while underlying NPAT climbed 90% to $1.6m, supported by a solid balance sheet despite increased inventory investment.
The company resolved a key patent dispute with Bluestone Pharma, jointly securing relevant patent applications and extending a five-year supply agreement that underpins its European ingredient business. BLIS further bolstered its IP portfolio with two new patents, expanded its Probi AB licensing deal into North America, EMEA and pet nutrition, advanced China regulatory trials, and set FY27 priorities around accelerating growth, R&D and brand-building in the growing oral probiotics market.
More about BLIS Technologies Limited
BLIS Technologies Limited is an NZX-listed manufacturer of advanced probiotic strains targeting oral and related health conditions. The company develops evidence-based probiotic solutions for throat health, halitosis, immune support, teeth and gum health, and skin health, selling its products across New Zealand, Asia, Europe and the USA.
Average Trading Volume: 278,322
Technical Sentiment Signal: Hold
Current Market Cap: N$19.19M
For an in-depth examination of BLT stock, go to TipRanks’ Overview page.